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Background: Prevention of bladder cancer recurrence is a central challenge in the management of this highly
prevalent disease. The histone deacetylase inhibitor valproic acid (sodium valproate) has anti-angiogenic properties
and has been shown to decrease bladder cancer growth in model systems. We have previously shown reduced
expression of thrombospondin-1 in a mouse model and in human bladder cancer relative to normal urothelium.
We speculated that inhibition of angiogenesis by valproate might be mediated by this anti-angiogenic protein.
Methods: Bladder cancer cell lines UMUC3 and T24 were treated with valproate or another histone deacetylase
inhibitor, vorinostat, in culture for a period of three days. Proliferation was assessed by alamar blue reduction. Gene
expression was evaluated by reverse transcription of RNA and quantitative PCR.
Results: Proliferation assays showed treatment with valproate or vorinostat decreased proliferation in both cell
lines. Histone deacetylase inhibition also increased relative expression of thrombospondin-1 up to 8 fold at 5 mM
valproate.
Conclusions: Histone deacetylase inhibitors warrant further study for the prevention or treatment of bladder
cancer.
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Bladder cancer is the fourth most commonly diagnosed
cancer in the United States with over 60,000 new cases
per year [1]. Fortunately, the majority of these cancers
are superficial and successfully treated surgically. Unfor-
tunately, these patients require intense follow-up due to
high recurrence rates and the potential for progression
to invasive cancer. Cystoscopy is recommended at regu-
lar intervals and even the lowest risk patients have a
30% recurrence rate at 5 years [2]. This constant need
for surveillance imposes economic and life style hard-
ship. An effective therapy to decrease bladder cancer* Correspondence: reederj@upstate.edu
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reproduction in any medium, provided the orrecurrence could have significant impact on both quality
of life and survival for over 500,000 patients with a his-
tory of bladder cancer in the United States alone.
Post-translational histone modifications such as acetyl-
ation are associated with transcriptionally active regions
of the genome. Histone deacetylation appears to be a
mechanism whereby cancers decrease expression of
genes involved in cell cycle control and apoptosis. His-
tone deacetylase inhibitors (HDACi) are an emerging
class of cancer drugs that might be useful in preventing
bladder cancer recurrence. Valproic acid (sodium valpro-
ate) is a relatively weak HDACi but has demonstrated
potential in the treatment of glioblastomas [3], thyroid
cancer [4], and leukemia [5]. There are several on-
going clinical trials of valproate for the treatment of
other cancers registered on ClinicalTrials.gov. Extensve
clinical experience with valproate as a seizure medica-
tion demonstrates that it is generally a well-toleratedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these reasons valproate is an attractive candidate for
the prevention of bladder cancer recurrence.
Anti-neoplastic properties of valproate in bladder can-
cer models have recently been reported by several
groups. Valproate decreased proliferation (or viability) of
TCC-SUP, T24, RT4, and HT1376 cell lines; increased
histone H3 acetylation and p21 expression and activated
caspase 2 and caspase 3 in T24 cells [6]. In addition,
in vitro invasiveness was decreased in valproate treated
T24, TCC-SUP, and HT1376 cells. This is not restricted
to in vitro studies: T24 xenografts had reduced growth
with chronic administration of valproate (0.4% in drink-
ing water for 35 days) in male athymic nu/nu mice.
Similar results were reported by Byun et al. [7] for TCC-
SUP and 5637 cell lines (identified in the publication by
their ATCC Numbers as HTB5 and HTB9 respectively).
Histone deacetylase 1 is expressed at higher levels in
human bladder cancer compared to normal urothelium
and its expression is also increased in the BBN mouse
bladder cancer model [8]. These authors also reported
delayed BBN-induced bladder tumors in mice. Valproate
decreased proliferation in UMUC3, RT112, TCCSUP, and
RT4 bladder cancer cell lines and, increased the percent-
age of cells in the G1 phase of the cell cycle with con-
comitant changes in cell cycle regulatory proteins [9].
Thrombospondin-1 (TSP1) is a well known natural in-
hibitor of angiogenesis. TSP1 anti-angiogenesis activity is
mediated at least in part through the CD36 receptor,
which initiates a cascade of events culminating in death of
endothelial cells [10]. TSP1 expression in the urinary blad-
der is altered in bladder cancer and associated with low
nuclear p53, increased tumor recurrence, and decreased
survival [11]. Cultured bladder cancer cell lines stimulated
to migrate and neovascularization showed lower TSP1 ex-
pression compared to normal urothelial cells, suggesting
that bladder tumors may selectively down regulate TSP1
thus promoting angiogenesis [12].
We have previously shown that TSP1 expression is
reduced in the bladders of UPII-SV40T transgenic mice
relative to wildtype littermates [13]. UPII-SV40T mice
develop bladder cancer due to urothelium-specific ex-
pression of the simian virus 40 T antigen protein [14].
Tumor growth was reduced and TSP1 expression
increased by castration. One of us (CS) investigating the
teratogenic properties of valproate noted that TSP1 ex-
pression was enhanced in embryos carried by dams trea-
ted with valproate (unpublished results). We speculated
that the anti-angiogenic action of valproate might be
due to increases in TSP1 expression in addition to a dir-
ect effect on cancer cell proliferation.
Here we report that valproate does induce TSP1 ex-
pression in bladder cancer cell lines and that this is
likely mediated through HDAC inhibition. The latterwas evidenced by increased TSP1 expression in response
to another HDAC inhibitor vorinostat (SAHA).
Methods
Tissue culture
UMUC-3 (ATCC CRL-1749) and T-24 (ATCC HTB-4)
bladder cancer cell lines were purchased from the
American Type Culture Collection (ATCC). They were
grown and subcultured in Dulbecco’s Minimal Essential
Medium, 10% fetal bovine serum, and 1% penicillin/
streptomycin media at 37C in a 5% CO2 incubator.
HDAC inhibitors
Sodium valproate was purchased from Westward Phar-
maceuticals (Eatontown, NJ) as a stock solution at
100 mg / ml. SAHA was purchased as a dry powder and
reconstituted in dimethyl sulfoxide at 0.5 M and stored
at -20C.
Proliferation assay
Both cell lines were plated at low seed onto a 24 well
plate. This was allowed overnight incubation. The fol-
lowing day, the media was removed and replaced with
media containing preset concentrations of valproate or
SAHA. These were incubated for 72 hours. At that
point, the media was removed and media containing no
treatment but supplemented with 10% Alamar blue was
added. This was allowed to incubate for three hours at
which point absorbance was read at 570 and 600 nm.
Each condition had four replicates. The ratio of absorb-
ance at 570 to 600 nm was scaled from zero for the no
cell wells to 100% for the no treatment wells. The data
were analyzed by t-test using JMP Statistical Software.
Expression analysis
Cells were grown in 25 cm2 T-flasks and treated with
valproate from 0 mM to 5 mM while SAHA was dosed
at 1 μM and 5 μM. The cultures were viewed daily and
ensured that the cells had not reached confluence. Cul-
tures were carried out 72 hours at which time the cells
were harvested for RNA extraction. This is comparable
to previous reports in which a three-day incubation was
needed prior to changes being evident [9]. Cells were
photographed at day 0 and day 3 prior to RNA harvest.
RNA extraction
After 72 hours treatment, the cells were scraped into PBS
and RNA extracted using an RNAeasy kit (Qiagen). RNA
was quantified using a NanoDrop spectrophotometer to
measure absorbance at 260 nm. Yields ranged from 2.7 μg
to 460 μg total RNA and were inversely proportional to
HDAC inhibitor dose. The ratio of absorbance at 260 nm
to absorbance at 280 was 2.0 to 2.1 for all specimens.
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Reverse transcription was performed according to manu-
facturer’s instructions using the Verso cDNA kit
(Thermo) in a 20 μl reaction. One μg total RNA was
denatured for 5 minutes at 70°C then cDNA synthesized
for 30 minutes at 42°C utilizing random hexamer prim-
ing and the RNA enhancer additive.
Quantitative PCR
Each cDNA reaction was diluted with 140 μL of molecu-
lar grade water. PCR primers all spanned at least one in-
tron. Primer Details are in Table 1. The reactions
consisted of 10 μL sybr green master mix (Roche), 1 μL
of 5 mM primer each, and 8 μL of cDNA diluted tem-
plate. PCR conditions were 95°C for 5 minutes, 95°C for
10 seconds, 60°C for 10 seconds, and 72°C for 30 seconds
for 60 cycles. Melting analysis was performed from 65°C
for to 97°C with 0.11 C/s ramp rate on a Roche Light
Cycler 480. Primers included heat shock protein 90
(HSP 90), bax transmembrane protein (BAX),
thrombospondin-1 (TSP1), ATP Synthase 5B, beta-actin
and hemeoxygenase-1 (HO-1). Reference genes were
selected according to Andersen [15]. All reactions were
performed in triplicate.
RT-PCR data analysis
A geometric mean was taken of the 4 reference genes
and used a standard comparison [16]. The delta-delta
CT method was used to calculate relative fold change in
expression differences between samples [17]. The data
were analyzed by t-test using JMP Statistical Software.




T24 and UMUC3 cell lines were treated with 1 mM and
5 mM valproate and 1 μM and 5 μM SAHA. Both cell
lines showed a reduction in mitotic figures and prolifera-
tion under phase contrast (Figure 1). The UMUC3 cell
line had a profound change in cellular morphology dis-
playing long dendrite-like processes. Alamar blue was
used to assay cell number following three days of drugTable 1 qPCR primers






HO-1 GGTGATAGAAGAGGCCAAGACexposure. Cell numbers were reduced by both drugs in
both cell lines (Figure 2).
TSP1 expression in response to HDAC inhibitors
TSP1 is an extracellular matrix protein whose expression
was assessed using quantitative reverse transcription
PCR (qPCR) and delta-delta-CT relative to the geomet-
ric mean of four reference genes, beta-actin, BAX,
HSP90, and ATP Synthase. T24 and UMUC3 cells were
grown in 25 cm2 tissue culture flasks and treated with
0.5, 1.0, 2.5, 5.0 mM valproate, and 1.0 or 5.0 μM SAHA
for three days. At 5 μM SAHA RNA yields were insuffi-
cient for analysis indicating a cytotoxic dose. The qPCR
results are presented in Figure 3. TSP1 expression in the
UMUC3 cells was significantly increased at doses of
1.0 mM and higher and was over 8-fold higher relative
to control at 5 mM. SAHA at 1 μM increased TSP1 ex-
pression more than three-fold as well. Similar results
were obtained for the T24 cell line with a dose
dependent increase in TSP1 expression, and was signifi-
cant at 0.5 mM and higher concentrations of valproate
reaching 6-fold levels at 5 mM. SAHA induced TSP1 ex-
pression almost four fold in the T24 cells.
Discussion
The primary goal of our study was to investigate the
effects of valproate on bladder cancer cells and provide a
possible mechanism for these effects. First, we confirmed
decreased proliferation with histone deacetylase inhibition
in the two bladder cancer cell lines, T24 and UMUC-3.
Second, we demonstrated that valproate increased TSP1
production, evidenced by increased mRNA expression.
The UMUC-3 cell line also displayed profound morpho-
logical changes with valproate. The dendritic processes are
consistent with urothelial umbrella cell differentiation.
These data support the hypothesis that valproic acid exerts
a negative effect on bladder cancer growth and shift to a
more differentiated state.
TSP1 expression has been noted to be lower in bladder
cancer specimens [13] and it is a potent anti-angiogenic
mediator [18]. Other work suggests that valproate acid is
an inhibitor of angiogenesis through direct effects on
endothelial cells [19]. A connection between HDAC inhib-







Figure 1 Phase contrast images (original magnification 100X) showing the impact of HDAC inhibitor treatment at the indicated
concentration for three days. Note the lower cell numbers in the treated cells and morphological changes consistent with a more
differentiated urothelial cell type.
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genesis in cancer by its action on TSP1 expression. The
exophytic growth of bladder tumors is dependent on
angiogenic support, inhibition of angiogenesis could slow
growth and possibly kill bladder tumors.
Valproate is a drug with a long clinical history for the
treatment of seizures. The toxicity profile for valproate
is acceptable for its possible use in chemoprevention of
bladder cancer. The recommended therapeutic level of
valproic acid for the treatment of seizures is generally
accepted to be between 50–125 ug/mL in humans [20].
At the high end this serum level is 0.75 mM. A recent
study looked at valproic acid induced proliferative
changes in ovarian cancer cells [21] Cytotoxic effects of
valproic acid were noted above 2.5 mM which is consist-
ent with our findings.Figure 2 Relative cell numbers by alamar blue assay for bladder canc
indicated concentrations. Statistically significant differences (t-test, p < 0.0
reductions in cell number for all treatment conditions relative to untreated
valproate condition showed significant reduction in T24 cell number.Changes in RNA expression do not necessarily lead to
changes in protein levels and we did not assess TSP1
protein levels in this in vitro study. TSP1 is a large mul-
timeric secreted protein with biologically active cleavage
products. Capture of the protein from media and/or the
tissue culture substrate presents several technical chal-
lenges. In addition, it is not our contention that TSP1
acts on the cancer cell, rather that normalizing TSP1 ex-
pression in cancer cells could decrease angiogenesis
through TSP1 action on endothelial cells.
HDAC inhibitors are attracting attention for the treat-
ment of several cancers. For example, SAHA has been
approved for the treatment of cutaneous T cell leukemia.
Our data and previous reports show direct effects of both
SAHA and valproate on bladder cancer cells in vitro and
suggest that anti-angiogenic properties of this class ofer cell lines treated for three days with HDAC inhibitors at the
5) from control are indicated by *. There were statistically significant
controls for UMUC3 cells. Similarly, all treatments except the 1 mM
Figure 3 Induction of TSP1 mRNA expression by HDAC inhibitors in bladder cancer cell lines. Statistically significant differences
(t-test, p < 0.05) relative to control are indicated by *. Cells were treated for three days with indicated drugs and concentrations. TSP1 expression
increased with dose in both cell lines. The increase was statistically significant at and above 1 mM valproate for UMUC3 and at and above
0.5 mM valproate for T24 cells. SAHA treatment at 1 μM induced TSP1 in both cell lines but decreased cell viability at 5 μM to the point that RNA
yields were insufficient for qPCR analysis.
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angiogenic protein TSP1. An effective low cost drug such
as valproate might decrease bladder cancer recurrence
and greatly benefit bladder cancer survivors.Conclusions
In conclusion, we confirm decreased proliferation of
bladder cancer cells by treatment with HDAC inhibitors
and show increased expression of TSP1 in bladder can-
cer by this class of drug. This is a novel mechanism for
bladder cancer control which can be exploited in future
clinical trials.
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